{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:03:20Z","timestamp":1789682600732,"version":"4.0.1"},"reference-count":26,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Patients with early-stage non-small cell lung cancer (NSCLC) or limited lung metastases and compromised lung function, such as those with interstitial lung disease (ILD) or chronic obstructive pulmonary disease (COPD), or other factors rendering them high-risk for surgery or medically inoperable, face increased risks of treatment-related toxicity from stereotactic ablative radiation therapy (SABR). This study evaluated a novel treatment approach to mitigate these risks. Methods: We investigated Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy (PULSAR), delivered as pulsed radiation every three weeks, in patients with &lt;5 cm lung tumors and ILD, COPD, or prior therapy. Treatment occurred between 2022 and 2024. Online adaptive radiotherapy (o-ART) was employed in 20 patients (80%) to modify treatment plans when anatomical changes warranted replanning. Primary outcomes included volumetric tumor response, changes in dose to organs at risk (OARs) and acute events, while secondary outcomes included local and tumor control, and overall survival. Results: Twenty-three patients received PULSAR treatment at doses between 40 Gy and 60 Gy in 5 fractions and one patient received 54 Gy in 3 fractions, with a median follow-up time of 16.2 months. Approximately half of treated patients demonstrated volumetric tumor response, with median residual volume of 70% (range 36\u2013100%) at maximal response. Among the 20 patients (80%) who underwent online adaptive replanning, significant reductions in OAR dosimetry were observed for all organs assessed including the Dmax for heart (p = 0.0053), bronchus (p = 0.0003), esophagus (p = 0.0005), spinal cord (p = 0.025), and the lung V20 Gy and V12.5 Gy (p &lt; 0.0001). Treatment-related toxicity included two grade 1\u20132 adverse events and six grade 3 events consisting of pneumonitis, dyspnea or lung infection, with no grade 4 or 5 events. Median progression-free survival was 21.1 months, with 1-year overall survival of 74% and 1-year local control of 100%. Conclusions: PULSAR shows promise as a feasible treatment option for high-risk patients with NSCLC or lung metastases, demonstrating no grade 5 events and complete tumor control. Additional research is needed to fully evaluate the safety profile of PULSAR in the high-risk subgroups and whether PULSAR\u2019s treatment intervals and adaptive planning advantages lead to improved long-term outcomes compared to conventional, uninterrupted SABR regimens.<\/jats:p>","DOI":"10.3390\/jcm15031261","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:35:37Z","timestamp":1770287737000},"page":"1261","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy (PULSAR) for Patients with Lung Tumors and Severe Pulmonary Disease"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3653-5923","authenticated-orcid":false,"given":"Kenneth D.","family":"Westover","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA"},{"name":"Department of Biochemistry, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4123-3807","authenticated-orcid":false,"given":"Ruiqi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4160-0451","authenticated-orcid":false,"given":"Stetler","family":"Tanner","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Aliru","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu-Han","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5915-3664","authenticated-orcid":false,"given":"Bin","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4466-0647","authenticated-orcid":false,"given":"David","family":"Parsons","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Visak","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesenia","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anundip","family":"Gill","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahed N.","family":"Badiyan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneeth","family":"Iyengar","sequence":"additional","affiliation":[{"name":"MSKCC\u2014Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2462-1007","authenticated-orcid":false,"given":"Robert","family":"Timmerman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.ijrobp.2014.05.135","article-title":"Long-term Results of RTOG 0236: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Medically Inoperable Stage I Non-Small Cell Lung Cancer","volume":"90","author":"Timmerman","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2018.1251","article-title":"Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial","volume":"4","author":"Timmerman","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology\/RTOG 0813 Trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2008.21.5681","article-title":"Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non\u2013Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy","volume":"27","author":"Baumann","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S252","DOI":"10.1016\/j.jtho.2019.08.503","article-title":"MA02.02 Toxicity of Lung SABR in Patients with Coexisting Interstitial Lung Disease","volume":"14","author":"Finazzi","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamaoncol.2023.7269","article-title":"Stereotactic Radiation Therapy in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Nonrandomized Clinical Trial","volume":"10","author":"Palma","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10147-019-01432-y","article-title":"Stereotactic body radiotherapy in patients with chronic obstructive pulmonary disease and interstitial pneumonia: A review","volume":"24","author":"Doi","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jtho.2017.02.021","article-title":"Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm","volume":"12","author":"Tekatli","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.radonc.2008.07.019","article-title":"Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer\u2014A first report of toxicity related to COPD\/CVD in a non-randomized prospective phase II study","volume":"88","author":"Baumann","year":"2008","journal-title":"Radiother. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/0284186X.2018.1468088","article-title":"Stereotactic body radiotherapy for second primary lung cancer and intra-parenchymal lung metastasis in patients previously treated with surgery: Evaluation of indications and predictors of decreased respiratory function","volume":"57","author":"Ishihara","year":"2018","journal-title":"Acta Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1378\/chest.11-1193","article-title":"Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy","volume":"141","author":"Takeda","year":"2012","journal-title":"Chest"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijrobp.2021.03.047","article-title":"Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Preclinical Models Enhances Single-Agent Immune Checkpoint Blockade","volume":"110","author":"Moore","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ijrobp.2007.07.2369","article-title":"Adaptive radiotherapy planning on decreasing gross tumor volumes as seen on megavoltage computed tomography images","volume":"69","author":"Woodford","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","article-title":"Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: An open-label, randomised, phase 2 trial","volume":"402","author":"Chang","year":"2023","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.prro.2023.04.003","article-title":"Consensus Quality Measures and Dose Constraints for Lung Cancer From the Veterans Affairs Radiation Oncology Quality Surveillance Program and ASTRO Expert Panel","volume":"13","author":"Puckett","year":"2023","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.ijrobp.2011.03.005","article-title":"Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: Stereotactic radiotherapy outcomes and systematic review","volume":"82","author":"Palma","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.21037\/jtd.2018.05.75","article-title":"Lung cancer and interstitial lung disease: A literature review","volume":"10","author":"Naccache","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ijrobp.2017.03.010","article-title":"Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease: A Systematic Review","volume":"98","author":"Chen","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","article-title":"A multidimensional index and staging system for idiopathic pulmonary fibrosis","volume":"156","author":"Ley","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4103\/atm.ATM_438_20","article-title":"Predictors of mortality in interstitial lung disease patients without pulmonary hypertension","volume":"15","author":"Alhamad","year":"2020","journal-title":"Ann. Thorac. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1513\/AnnalsATS.202301-014OC","article-title":"Diffusing Capacity as a Predictor of Hospitalizations in a Clinical Cohort of Chronic Obstructive Pulmonary Disease","volume":"21","author":"Balasubramanian","year":"2024","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5603\/RPOR.a2022.0005","article-title":"Radiobiology of stereotactic radiotherapy","volume":"27","author":"Mangoni","year":"2022","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Xiao, Y., and Zhuang, H. (2022). Effect of stereotactic radiotherapy on immune microenvironment of lung cancer. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1025872"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13014-018-1080-4","article-title":"Repeat stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell lung cancer and lung metastasis after first SBRT","volume":"13","author":"Ogawa","year":"2018","journal-title":"Radiat. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jamaoncol.2019.0205","article-title":"Analysis of Toxic Effects With Antiangiogenic Agents Plus Stereotactic Body Radiation in Ultracentral Lung Tumors","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/1261\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:55:29Z","timestamp":1770288929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/1261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jcm15031261"],"URL":"https:\/\/doi.org\/10.3390\/jcm15031261","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]}}}